Opus Genetics, Inc. (IRD) Earnings History
Annual and quarterly earnings data from 2019 to 2024
Loading earnings history...
IRD EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
IRD Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -564.7% | -523.4% |
| 2023 | 100.0% | -55.5% | -52.4% |
| 2022 | 100.0% | 45.7% | 44.9% |
| 2021 | 100.0% | -3854.8% | -9625.3% |
| 2020 | - | - | - |
Download Data
Export IRD earnings history in CSV or JSON format
Free sign-in required to download data
Opus Genetics, Inc. (IRD) Earnings Overview
As of May 8, 2026, Opus Genetics, Inc. (IRD) reported trailing twelve-month net income of -$68M, reflecting -367.4% year-over-year growth. The company earned $-0.97 per diluted share over the past four quarters, with a net profit margin of -523.4%.
Looking at the long-term picture, IRD's historical earnings data spans multiple years. The company achieved its highest annual net income of $18M in fiscal 2022.
Opus Genetics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including REPL (-$315M net income), JANX (-$158M net income, -1576.7% margin), KRYS ($225M net income, 52.6% margin), IRD has comparable earnings metrics. Compare IRD vs REPL →
IRD Earnings vs Peers
Earnings metrics vs comparable public companies
IRD Historical Earnings Data (2019–2024)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$58M | -476.1% | -$62M | $-2.15 | -523.4% | -564.7% |
| 2023 | -$10M | -155.8% | -$11M | $-0.46 | -52.4% | -55.5% |
| 2022 | $18M | +131.6% | $18M | $0.87 | 44.9% | 45.7% |
| 2021 | -$57M | -130.3% | -$23M | $-3.82 | -9625.3% | -3854.8% |
| 2020 | -$25M | -299.1% | -$20M | $-5.28 | - | - |
| 2019 | -$6M | - | -$4M | $-0.87 | - | - |
See IRD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IRD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IRD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIRD — Frequently Asked Questions
Quick answers to the most common questions about buying IRD stock.
Is IRD growing earnings?
IRD EPS fell to $-0.97, with earnings declining -367.4%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-68M.
What are IRD's profit margins?
Opus Genetics, Inc. net margin is -523.4%, with operating margin at -564.7%. Below-average margins reflect competitive or cost pressures.
How consistent are IRD's earnings?
IRD earnings data spans 2019-2024. The declining earnings trend is -367.4% YoY. Historical data enables comparison across business cycles.